Loading organizations...
True Light Capital is an asset manager specializing in investment opportunities tied to Greater China. The firm manages funds, deploying a theme-driven approach across asset classes, sectors, and stages. This strategy enables identification and investment in high-quality regional enterprises, building portfolios to perform through market cycles.
Established in Singapore in 2021, True Light Capital's formation stemmed from insight into Greater China's dynamic investment landscape. The firm aims to provide sophisticated asset management with deep regional understanding, strategically deploying capital to promising ventures. Its establishment emphasizes long-term value creation through disciplined investing.
The firm primarily serves global institutional and accredited investors seeking exposure to Greater China's vibrant economy. True Light Capital envisions becoming a leading asset manager, known for regional expertise and fostering innovative growth. It strives to generate consistent returns by strategically navigating this critical market.
TrueLight Capital has 3 tracked investments across 3 companies. The latest tracked deal is $85.9M Series C in Baoling Bio in January 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 16, 2026 | Baoling Bio | $85.9M Series C | Qiming Venture Partners, Truelight Capital | 5Y Capital, Guosheng Capital |
| Dec 5, 2025 | OTR Therapeutics | $100.0M Series A | — | YI SHI, Sirona Capital |
| Jul 25, 2022 | JAKA Robotics | $150.0M Series D | Scott CAI, Softbank, Temasek, Truelight Capital | — |
